Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) (LUPSENIC)
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)
Sponsor: Medsenic Company
Terminated
Difficulty of inclusions and a sufficient number of relevant clinical information
Other Systemic Lupus trials with similar outcome
A PHASE2 clinical study on Systemic Lupus, this trial is terminated or withdrawn. The trial is conducted by Medsenic Company and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medsenic Company
- Nantes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .